Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

BACKGROUND: Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas were effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shekhar, Tanmay M., Burvenich, Ingrid J. G., Harris, Michael A., Rigopoulos, Angela, Zanker, Damien, Spurling, Alex, Parker, Belinda S., Walkley, Carl R., Scott, Andrew M., Hawkins, Christine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744692/
https://www.ncbi.nlm.nih.gov/pubmed/31521127
http://dx.doi.org/10.1186/s12885-019-6103-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744692/
https://www.ncbi.nlm.nih.gov/pubmed/31521127
http://dx.doi.org/10.1186/s12885-019-6103-5

Ejemplares similares